In vitro inhibition of the activation of pro-matrix metalloproteinase 1 (pro-MMP-1) and pro-matrix metalloproteinase 9 (pro-MMP-9) by rice and soybean Bowman-Birk inhibitors

Journal of Agricultural and Food Chemistry

Volumn 52, Issue 15, 2004, Pages 4730-4736

  Bawadi, Hiba A ^a   Antunes, Tania Maria ^a   Shih, Fred ^b   Losso, Jack N ^a  

^a LOUISIANA STATE UNIVERSITY AGRICULTURAL CENTER   (United States)

^b SOUTHERN REGIONAL RESEARCH CENTER   (United States)

Author keywords

Angiogenesis; Bowman Birk Inhibitor; Functional food Ingredient; Metalloproteinase 1; Metalloproteinase 9

Indexed keywords

BOWMAN BIRK INHIBITOR; ENZYME PRECURSOR; GELATIN; GELATINASE B; HEPARIN; INTERSTITIAL COLLAGENASE; TRYPSIN;

ANGIOGENESIS; ARTICLE; BRAN; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME SUBSTRATE; HYDROLYSIS; NONHUMAN; PLANT; POLYACRYLAMIDE GEL ELECTROPHORESIS; RICE; SOYBEAN;

BIOTINYLATION; COLLAGENASES; ENZYME ACTIVATION; ENZYME PRECURSORS; FLUORESCENCE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 9; ORYZA SATIVA; PROTEASE INHIBITORS; SOYBEANS; TRYPSIN; TRYPSIN INHIBITOR, BOWMAN-BIRK SOYBEAN;

GLYCINE MAX;

EID: 3242815965     PISSN: 00218561     EISSN: None     Source Type: Journal    
DOI: 10.1021/jf034576u     Document Type: Article

References (36)

1. Folkman, J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 2002, 29 (6 Suppl, 16), 15-18.
2. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285, 1182-1186.
3. Chang, C.; Werb, Z. The many faces of metalloproteases: cell growth, invasion, angio-genesis and metastasis. Trends Cell Biol. 2001, 11, S37-S43.
4. Yu, W. H.; Woesnner, J. F., Jr. Heparin-enhanced zymographic detection of matrilysin and collagenase. Anal. Biochem. 2001, 293, 38-42.
5. Duncan, M. E.; Richardson, J. P.; Murray, G. I.; Melvin, W. T.; Fothergill, J. E. Human matrix metalloproteinase-9: activation by limited trypsin treatment and generation of monoclonal antibodies specific for the activated form. Eur. J. Biochem 1998, 258, 37-43.
6. Theret, N.; Musso, O.; L'Helgoualc'h, A.; Clement, B. Activation of matrix metalloproteinase-2 from hepatic stellate cells requires interactions with hepatocytes. Am. J. Pathol. 1997, 150, 51-58.
7. Otani, Y.; Kubota, T.; Sakura, Y.; Igarashi, N.; Ypkoyama, T.; Kimata, M.; Wada, N.; Kameyama, K.; Kumai, K.; Okada, Y.; Kitajima, M. Expression of matrix metalloproteinases in gastric carcinoma and possibility of clinical application of matrix metalloproteinase inhibitor in vivo. Ann. N. Y. Acad. Sci. 1999, 878, 541-543.
8. Scappaticci, F. A. Mechanism and future directions for angiogenesis-based cancer therapies. J. Clin. Oncol. 2002, 18, 3906-3927.
9. Baker, E. A.; Bergin, F. G.; Leaper, D. J. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging. Br. J. Surg. 2000, 87, 1215-1221.
10. Hrabec, E.; Strek, M.; Nowak, D.; Hrabec, Z. Elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer. Resp. Med. 2001, 95, 1-4.
11. Gingras, D.; Batist, G.; Beliveau, R. AE-941 (Neovastat): a novel multifunctional antiangiogenic compound. Expert. Rev. Anticancer Ther. 2001, 1, 341-347.
12. Tashiro, M.; Hashino, K.; Shiozaki, M.; Ibuki, F.; Maki, Z. The complete amino acid sequence of rice bran trypsin inhibitor. J. Biochem. (Tokyo) 1987, 102, 297-306.
13. Kennedy, A. R.; Billings, P. C.; Wan, X. S.; Newberne, P. M. Effects of Bowman-Birk inhibitor on rat colon carcinogenesis. Nutr. Cancer 2002, 43, 174-186.
14. Lippman, S. M.; Matrisian, L. M. Protease inhibitors in oral carcinogenesis and chemoprevention. Clin. Cancer Res. 2000, 6, 4599-4603.
15. Losso, J. N. Preventing degenerative diseases with anti-angiogenic functional foods. Food Technol, 2002, 56, 78-88.
16. Tosetti, F.; Ferrari, N.; De Flora, S.; Albini, A. Angioprevention′ : angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J. 2002, 16, 2-14.
17. Losso, J. N. Targeting excessive angiogenesis with anti-angiogenic functional foods and nutraceuticals. Trends Food Sci. Technol. 2003, 14, 455-468.
18. Ratnikov, B.; Deryugina, E.; Leng, J.; Marchenko, G.; Dembrow, D.; Strongin, A. Determination of matrix metalloproteinase activity using biotinylated gelatin. Anal. Biochem. 2000, 286, 149-155.
19. Knight, C. G.; Willenbrock, F.; Murphy, G. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett. 1992, 296, 263-266.
20. Liener, I. E.; Goodale, R. L.; Deshmukh, A.; Satterberg, T. L.; Ward, G.; DiPietro, C. M.; Bankey, P. E.; Borner, J. W. Effect of a trypsin inhibitor from soybeans (Bowman-Birk) on the secretory activity of the human pancreas. Gastroenterology 1988, 94, 419-427.
21. Malykh, E. V.; Larionova, N. I. Study of antiproteinase activity of acylated derivatives of Bowman-Birk soybean proteinase inhibitor. Biochemistry (Moscow) 2002, 67, 1383-1387.
22. Rao, C. N.; Mahanam, S.; Puppala, A.; Rao, J. S. Regulation of pro-MMP-1 and pro-MMP-3 activation by tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor. Biochem. Biophys. Res. Commun. 1999, 255, 94-98.
23. Sharma, S.; Ghoddoussi, M.; Gao, P.; Kelloff, G. J.; Steele, V. E.; Kopelovich, L. A quantitative angiogenesis model for efficacy testing of chemopreventive agents. Anticancer Res. 2001, 21, 3829-3837.
24. Okada, Y.; Gonoji, Y.; Naka, K.; Tomita, K.; Nakanishi, I.; Iwata, K.; Yamashita, K.; Hayakawa, T. Matrix metalloprotease 9 (92-kDa gelatinase/Type IV collagenase) from HT 1080 human fibrosarcoma cells. J. Biol. Chem. 1992, 267, 21712-21719.
25. Okamoto, T.; Akaike, T.; Suga, M.; Tanase, S.; Horie, H.; Miyajima, S.; Ando, M.; Ichinose, Y.; Maeda, H. Activation of human matrix metalloproteinases by various bacterial proteinases. J. Biol. Chem. 1997, 272, 6059-6066.
26. Heather, E. I.; Grochow, L. B. Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs 2000, 59, 1043-1055.
27. 2+ in activation and catalysis. J. Biol. Chem. 1995, 270, 18563-18569.
28. Hashimoto, K.; Nagao, Y.; Kato, K.; Mori, Y.; Ito, A. Human urinary trypsin inhibitor inhibits the activation of pro-matrix metalloproteinases and proteoglycans release in rabbit articular cartilage. Life Sci. 1998, 63, 205-213.
29. Yavelow, J.; Finlay, T. H.; Kennedy, A. R.; Troll, W. A. Bowman-Birk soybean protease inhibitor as an anticarcinogen. Cancer Res. 1983, 43, 2454-2459.
30. Jensen, B.; Unger, K. K.; Uebe, J.; Gey, M.; Kim, Y.-M.; Flecker, P. Proteolytic cleavage of soybean Bowman-Birk inhibitor monitored by means of high-performance capillary electrophoresis. Implications for the mechanism of proteinase inhibitors. J. Biochem. Biophys. Methods 1996, 33, 171-185.
31. Kennedy, A. R. Chemopreventive agents: protease inhibitors. Pharmacol. Ther. 1998, 78, 167-209.
32. Billings, P. C.; Habres, J. M.; Liao, D. C.; Tuttle, S. W. A protease activity in human fibroblasts which is inhibited by the anticarcinogenic Bowman-Birk protease inhibitor. Cancer Res. 1991, 51, 5539-5543,
33. Billings, P. C.; St. Clair, W. H.; Maki, P. A.; Kennedy, A. R. Distribution of the Bowman-Birk protease inhibitor in mice following oral administration. Cancer Lett. 1992, 62, 191-197.
34. Yavelow, J.; Collins, M.; Birk, Y.; Troll, W.; Kennedy, A. R. Nanomolar concentrations of Bowman-Birk soybean protease inhibitor suppress X-ray induced transformation in vitro. Proc. Natl. Acad. Sci. U.S.A. 1985, 82, 5395-5399.
35. St. Clair, W. H.; Billings, P. C.; Carew, J. A.; Keller-McGandy, C.; Newberne, P.; Kennedy, A. R. Suppression of dimethylhydrazine-induced carcinogenesis in mice by dietary addition of the Bowman-Birk protease inhibitor. Cancer Res. 1990, 50, 580-586.
36. Wan, X. S.; Lu, L. J. W.; Anderson, K. E.; Ware, J. H.; Kennedy, A. R. Urinary excretion of Bowman-Birk inhibitor in human after soy consumption as determined by a monoclonal antibody-based immunoassay. Cancer Epidemiol. Biomarkers Prev. 2000, 9, 741-747.